Anti-TNF switching: Effect on outcomes in patients with RA: Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 8, 2007, Pages 430-431

  Olsen, Nancy ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34547582031     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0535     Document Type: Short Survey

References (2)

1. Yazici Y et al. (2005) Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64: 207-211
2. Lindberg J et al. (2006) Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 8: R179